



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

| | |
|---------------|--|
| Last Trade: | 2.23 |
| Trade Time: | 8:00 PM ET 05/25/18 |
| Change: | 0.07 ↑ (3.241%) |
| Day Range | 2.15 - 2.25 |
| 52-Week Range | 1.42 - 4.37 |
| Volume | 282,664 |


Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- [05/15/18
Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage](#)
- [05/07/18
Rexahn Reports First Quarter 2018 Financial Results](#)
- [04/26/18
Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)
- [03/13/18
Rexahn Pharmaceuticals to Present at Two Upcoming Conferences](#)
- [03/12/18
Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- [03/09/18
Annual Report \(10-K\)](#)
- [04/23/18
Proxy Statement \(DEF 14A\)](#)
- [05/04/18
Quarterly Report \(10-Q\)](#)
- [11/03/17
Quarterly Report \(10-Q\)](#)
- [08/04/17
Quarterly Report \(10-Q\)](#)